美国 · SEC FORM 4
JOHNSON & JOHNSON
JNJ · NYSE · CIK 0000200406 · Healthcare · Drug Manufacturers—General
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
21 同一窗口内观察到的 Form 4 交易行
11 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-11-26 · MORIKIS JOHN G.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 22,070,973
- 上期报告
- 21,188,522
- 日均成交量
- 6,751,004
- 回补天数
- 3.3
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-11-26 | MORIKIS JOHN G | 买入 (P) | Common Stock | 1,250 | USD 206.15 | USD 257,688 | SEC 申报 ↗ |
| 2024-12-12 | WEINBERGER MARK A | 买入 (P) | Common Stock | 1,000 | USD 147.22 | USD 147,220 | SEC 申报 ↗ |
| 2024-04-30 | Woods Eugene A. | 买入 (P) | Common Stock | 100 | USD 145.53 | USD 14,553 | SEC 申报 ↗ |
| 2020-03-13 | PEREZ WILLIAM D | 买入 (P) | Common Stock | 500 | USD 127.69 | USD 63,845 | SEC 申报 ↗ |
Form 4 申报证据
142 transaction lines in the latest 365-day window; 811 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | 卖出 (S) | Common Stock | 33,597 | USD 274.74 | USD 9,230,440 | SEC 申报 ↗ |
| 2026-09-02 | Schmid Timothy | 期权行权/转换 (M) | Common Stock | 33,597 | USD 144.99 | USD 4,871,389 | SEC 申报 ↗ |
| 2026-08-17 | Taubert Jennifer L | 卖出 (S) | Common Stock | 15,000 | USD 263.36 | USD 3,950,400 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | 卖出 (S) | Common Stock | 33,597 | USD 274.74 | USD 9,230,440 | SEC 申报 ↗ |
| 2026-09-02 | Schmid Timothy | 期权行权/转换 (M) | Common Stock | 33,597 | USD 144.99 | USD 4,871,389 | SEC 申报 ↗ |
| 2026-08-17 | Taubert Jennifer L | 卖出 (S) | Common Stock | 15,000 | USD 263.36 | USD 3,950,400 | SEC 申报 ↗ |
| 2026-08-17 | Taubert Jennifer L | 期权行权/转换 (M) | Common Stock | 15,000 | USD 115.67 | USD 1,735,050 | SEC 申报 ↗ |
| 2026-08-13 | Duato Joaquin | 卖出 (S) | Common Stock | 123,291 | USD 261.17 | USD 32,199,927 | SEC 申报 ↗ |
| 2026-08-13 | Duato Joaquin | 期权行权/转换 (M) | Common Stock | 123,291 | USD 115.67 | USD 14,261,070 | SEC 申报 ↗ |
| 2026-08-06 | Forminard Elizabeth | 卖出 (S) | Common Stock | 15,918 | USD 257.00 | USD 4,090,993 | SEC 申报 ↗ |
| 2026-08-06 | Forminard Elizabeth | 期权行权/转换 (M) | Common Stock | 9,344 | USD 131.94 | USD 1,232,847 | SEC 申报 ↗ |
| 2026-08-05 | Duato Joaquin | 卖出 (S) | Common Stock | 48,480 | USD 258.15 | USD 12,515,184 | SEC 申报 ↗ |
| 2026-07-20 | Broadhurst Vanessa | 卖出 (S) | Common Stock | 23,054 | USD 251.27 | USD 5,792,779 | SEC 申报 ↗ |
| 2026-07-20 | Broadhurst Vanessa | 期权行权/转换 (M) | Common Stock | 23,054 | USD 130.77 | USD 3,014,701 | SEC 申报 ↗ |
| 2026-06-11 | Wengel Kathryn E | 卖出 (S) | Common Stock | 10,000 | USD 241.15 | USD 2,411,500 | SEC 申报 ↗ |
| 2026-06-11 | Wengel Kathryn E | 期权行权/转换 (M) | Common Stock | 10,000 | USD 115.67 | USD 1,156,700 | SEC 申报 ↗ |
| 2026-05-01 | REED JOHN C | 期权行权/转换 (M) | Common Stock | 25,255 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | REED JOHN C | 代扣税 (F) | Common Stock | 11,002 | USD 229.85 | USD 2,528,810 | SEC 申报 ↗ |
| 2026-02-27 | Decker Robert J | 卖出 (S) | Common Stock | 4,075 | USD 247.87 | USD 1,010,070 | SEC 申报 ↗ |
| 2026-02-27 | Decker Robert J | 期权行权/转换 (M) | Common Stock | 4,075 | USD 115.67 | USD 471,355 | SEC 申报 ↗ |
| 2026-02-20 | Schmid Timothy | 卖出 (S) | Common Stock | 1,322 | USD 245.66 | USD 324,763 | SEC 申报 ↗ |
| 2026-02-18 | Schmid Timothy | 卖出 (S) | Common Stock | 22,623 | USD 244.33 | USD 5,527,506 | SEC 申报 ↗ |
| 2026-02-18 | Schmid Timothy | 期权行权/转换 (M) | Common Stock | 22,623 | USD 121.17 | USD 2,741,335 | SEC 申报 ↗ |
| 2026-02-17 | Wolk Joseph J | 卖出 (S) | Common Stock | 89,654 | USD 242.80 | USD 21,767,827 | SEC 申报 ↗ |
| 2026-02-17 | Wolk Joseph J | 期权行权/转换 (M) | Common Stock | 64,693 | USD 126.65 | USD 8,193,223 | SEC 申报 ↗ |
| 2026-02-17 | Swanson James D. | 卖出 (S) | Common Stock | 20,521 | USD 242.70 | USD 4,980,447 | SEC 申报 ↗ |
| 2026-02-17 | Swanson James D. | 期权行权/转换 (M) | Common Stock | 20,521 | USD 164.62 | USD 3,378,167 | SEC 申报 ↗ |
| 2026-02-17 | REED JOHN C | 卖出 (S) | Common Stock | 53,931 | USD 243.00 | USD 13,105,233 | SEC 申报 ↗ |
| 2026-02-17 | REED JOHN C | 期权行权/转换 (M) | Common Stock | 51,648 | USD 156.89 | USD 8,103,281 | SEC 申报 ↗ |
| 2026-02-17 | Broadhurst Vanessa | 卖出 (S) | Common Stock | 6,197 | USD 243.39 | USD 1,508,288 | SEC 申报 ↗ |
| 2026-02-15 | Wolk Joseph J | 期权行权/转换 (M) | Common Stock | 3,849 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-15 | Wolk Joseph J | 代扣税 (F) | Common Stock | 1,675 | USD 243.45 | USD 407,779 | SEC 申报 ↗ |
| 2026-02-15 | Wengel Kathryn E | 期权行权/转换 (M) | Common Stock | 1,241 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | JNJ |
| CIK | 0000200406 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—General Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 811 transaction lines from 2020-01-30 to 2026-09-02 4 P purchase lines · 254 S sale lines · 553 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.